Syntara Secures FDA Support for Amsulostat Phase 2b Trial in Myelofibrosis and Raises $8M to Fuel Clinical Pipeline Growth

FDA Endorses Amsulostat Phase 2b Trial Design, Paving Regulatory Path Forward

In April 2026, Syntara received positive guidance from the US Food and Drug Administration following an in-person Type C meeting concerning its proposed Phase 2b clinical trial of amsulostat for myelofibrosis patients. The FDA reviewed the company’s clinical development progress and endorsed the study design, providing detailed protocol guidance and a clear development pathway for amsulostat. This represents a significant regulatory achievement, enabling advancement of the lead asset toward late-stage clinical development.

The upcoming Phase 2b trial will be a randomized, double-blind, placebo-controlled study enrolling approximately 100 myelofibrosis patients who have shown inadequate response to standard-of-care JAK inhibitor therapy. Amsulostat will be administered as an add-on to existing JAK inhibitor treatment, with the primary endpoint measuring the proportion of patients achieving at least a 50% reduction in total symptom score after nine months, a clinically meaningful indicator of symptom improvement. This positive regulatory feedback builds upon safety and efficacy data from the completed Phase 2a study, where amsulostat was assessed both as monotherapy and in combination with JAK inhibitors. The drug has previously earned FDA Fast Track and Orphan Drug designations, highlighting its potential to address unmet needs in patients with persistent symptoms despite current therapies.

$8.0 Million Institutional Placement Extends Financial Runway and Supports Clinical Progress

During the June quarter, Syntara completed an $8.0 million institutional placement, reinforcing its balance sheet and extending the cash runway into Q3 2027. This capital infusion equips the company to advance key clinical programs, deliver multiple data readouts in the latter half of 2026, and continue commercial and licensing negotiations with potential partners. The successful placement reflects strong investor confidence, especially following the positive FDA feedback on amsulostat.

CEO Gary Phillips emphasized that the capital raise, combined with regulatory progress, "provided the resources to advance our key programs, deliver multiple clinical readouts and progress ongoing commercial and licensing discussions." The extended financial runway allows Syntara to maintain recruitment and data generation momentum across trials while engaging actively with prospective commercial collaborators, positioning the company for potential partnerships or licensing deals as clinical data matures.

SNT-4728 Phase 2 Trial Shows Significant Reduction in Brain Inflammation Linked to Parkinson's Disease

Syntara announced preliminary results from its randomized, double-blind, placebo-controlled Phase 2 trial of SNT-4728 in patients with isolated REM Sleep Behaviour Disorder (iRBD), a condition associated with high risk of progression to Parkinson's disease and related neurodegenerative disorders. This trial is the first global interventional study targeting neuroinflammation in iRBD to investigate disease biology underlying Parkinson’s progression. Early data revealed a statistically significant reduction in inflammation within the putamen, a brain region critical to the motor symptoms of Parkinson’s disease.

The multi-centre trial enrolled 41 patients randomized 3:1 to receive SNT-4728 or placebo for 12 weeks. Besides safety and clinical symptom assessments, positron emission tomography imaging measured microglial activation and neuroinflammation across key brain regions. The study population was enriched for patients at elevated Parkinson’s risk, with 90% exhibiting reduced or absent sense of smell, 46% showing impaired color discrimination, and 95% testing positive for misfolded alpha-synuclein in cerebrospinal fluid. These biomarkers underscore the clinical relevance of the cohort for evaluating SNT-4728’s disease-modifying potential. Full clinical, imaging, digital, and biomarker data are expected in Q3 2026, providing a comprehensive efficacy and safety profile.

SNT-9465 Hypertrophic Scar Trial Surpasses Midpoint, Targeting Q3 2026 Recruitment Completion

SNT-9465, Syntara’s Phase 1b candidate for hypertrophic scar treatment, has achieved 60% treatment initiation as of the latest reporting period. Recruitment completion is targeted for Q3 2026, setting the stage for top-line results later that year. Hypertrophic scars, common after burns, surgery, and trauma, represent a significant clinical need with limited current treatment options, presenting a promising market opportunity for this novel therapy.

The Phase 1b trial evaluates safety and efficacy in patients with hypertrophic scars. Progressing beyond the halfway recruitment mark demonstrates strong enrolment across trial sites and supports timely completion. The anticipated data release in late 2026 adds to the company’s pipeline of near-term clinical catalysts.

AZALOX Myelodysplastic Syndrome Study Advances to Final Phase 1b Dose Cohort Without Dose-Limiting Toxicities

The AZALOX trial, assessing amsulostat combined with 5-Azacitidine (5-AZA) in high-risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukaemia (CMML) patients, has progressed to the final Phase 1b dose cohort. Following safety review by the independent Drug Safety Monitoring Board, escalation to 200 mg twice daily dosing of amsulostat with 5-AZA was approved. The initial cohort at 150 mg twice daily reported no dose-limiting toxicities or new adverse events attributable to amsulostat, confirming tolerability of the combination.

The Phase 1b segment aims to establish safety and determine the recommended Phase 2 dose. Upon completion and safety review of the 200 mg cohort, the study will advance to a Phase 2 component enrolling approximately 30 patients to assess safety and efficacy. All 10 German clinical sites are active and recruiting. Preliminary Phase 1b dose-escalation results are expected in Q4 2026. Concurrently, the Australasian Leukaemia & Lymphoma Group leads the Australian MDS05/D3 MESSAGE study evaluating amsulostat with oral hypomethylating agent ASTX727 in transfusion-dependent low and intermediate-risk MDS patients, with initial results anticipated in H1 2027.

Multiple Clinical Milestones and Data Releases Expected in H2 2026

Syntara anticipates a busy clinical calendar in the second half of 2026, with several data readouts and regulatory milestones. The full dataset from the SNT-4728 Phase 2 iRBD trial is expected in Q3 2026, complementing preliminary inflammation reduction findings. Recruitment completion for the SNT-9465 hypertrophic scar Phase 1b trial is also targeted for Q3 2026, followed by top-line results later that year. Preliminary data from the AZALOX Phase 1b dose-escalation cohort is due in Q4 2026. These milestones offer multiple near-term catalysts for investors.

Beyond these readouts, preparations continue for the FDA-supported Phase 2b myelofibrosis study of amsulostat. The company is actively engaging potential commercial partners across its pipeline, with licensing or development collaborations representing additional future catalysts. CEO Gary Phillips remarked that "the months ahead are expected to be highly active," balancing near-term data delivery with strategic partnership discussions to maximize shareholder value.

Diversified Clinical Pipeline Targets Oncology, Neurodegeneration, and Dermatology

Syntara’s clinical-stage pipeline spans oncology, neurodegenerative disease, and dermatology, providing diversified therapeutic exposure. Amsulostat targets myelofibrosis and myelodysplastic syndrome, addressing serious hematologic disorders with unmet needs. SNT-4728 focuses on neuroinflammation in iRBD, a Parkinson’s disease spectrum condition, while SNT-9465 aims to treat hypertrophic scars in dermatology. This multi-indication strategy reduces development risk and expands partnership and licensing opportunities.

The company’s revenue model aligns with clinical-stage biotech norms, relying on capital raises, milestone payments, and future licensing or partnership agreements as assets progress. Positive FDA feedback on amsulostat and progress across clinical programs enhance Syntara’s commercial profile and support ongoing discussions with potential partners. CEO Phillips highlighted "ongoing commercial and licensing discussions," indicating active exploration of collaborations to secure near-term capital and share development risk. The $8.0 million placement extends the financial runway, enabling these strategic efforts alongside clinical advancement.

FDA Fast Track and Orphan Drug Designations Support Amsulostat’s Development

Amsulostat holds FDA Fast Track and Orphan Drug designations, underscoring its potential to address unmet medical needs in rare and serious conditions. Fast Track status facilitates expedited FDA review, while Orphan Drug designation offers incentives including market exclusivity. Combined with the April 2026 Type C meeting feedback, these regulatory recognitions establish a favorable environment for amsulostat’s clinical progression. FDA agreement on the Phase 2b trial design and development pathway reduces risk of delays and protocol changes, providing regulatory certainty critical for late-stage development.

This alignment enhances amsulostat’s value in partnership discussions and investor confidence, offering a well-defined pathway toward potential approval contingent on successful Phase 2b results. The combination of designations and positive FDA engagement positions the asset for accelerated development.

Strong Clinical Recruitment and Rigorous Trial Designs Demonstrate Syntara’s Execution Strength

Syntara’s progress in recruiting patients across multiple trials highlights operational capability in a competitive clinical environment. The SNT-9465 trial has reached 60% treatment initiation with recruitment completion on track for Q3 2026. All 10 AZALOX sites in Germany are active and enrolling. The SNT-4728 Phase 2 trial successfully enrolled 41 patients globally despite complex imaging and biomarker assessments. These achievements reflect effective clinical trial management and strong investigator relationships.

The innovative trial designs further demonstrate scientific rigor. The SNT-4728 Phase 2 study is the first global interventional trial targeting neuroinflammation in iRBD, with patient selection enriched for Parkinson’s risk biomarkers such as hyposmia, color discrimination deficits, and misfolded alpha-synuclein in cerebrospinal fluid. These design elements increase the likelihood of detecting meaningful drug effects and provide compelling evidence of mechanism of action, supporting regulatory and partnership discussions. For investors, successful recruitment and sophisticated trial execution underscore Syntara’s clinical expertise and operational infrastructure to advance its ambitious development programs.